Education
About Us
Working with TipRanks
Follow Us
Silexion Therapeutics (SLXN)
NASDAQ:SLXN
SLXN Stock Chart & Stats
$2.12
-$0.10(-4.76%)
At close: 4:00 PM EST
$2.12
-$0.10(-4.76%)
Day’s Range― - ―
52-Week Range$1.51 - $26.70
Previous CloseN/A
Volume52.80K
Average Volume (3M)50.14K
Market Cap
$4.94M
Enterprise Value-$7.87M
Total Cash (Recent Filing)$9.24M
Total Debt (Recent Filing)$485.00K
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Mar 24, 2026EPS Estimate
-1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding3,126,642
10 Day Avg. Volume60,134
30 Day Avg. Volume50,136
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)-47.15
Price to Sales (P/S)0.00
P/FCF Ratio-22.34
Enterprise Value/Market Cap-1.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.12K
Enterprise Value/Ebitda1.05
Forecast
1Y Price Target
$9.00Price Target Upside324.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Broad, Potent Preclinical Efficacy Of SIL204Demonstrated >90% inhibition across multiple KRAS mutations and tumor types indicates a platform-level therapeutic effect. This breadth strengthens the company’s competitive position in pan-KRAS RNAi, increasing the odds of multiple clinical opportunities and strategic partnerships over the next 2–6 months and beyond.
Completion Of Toxicology With No Systemic Organ ToxicityClear two‑species toxicology with no systemic organ toxicity materially reduces preclinical safety risk ahead of human dosing. That durable de‑risking supports on-time regulatory filings, trial starts, and more credible partner discussions, improving execution probability for clinical milestones.
Regulatory Progress Toward Phase 2/3 TrialSubmission of a Phase 2/3 application plus positive regulator feedback provides structural clarity on trial design and pathway to pivotal data. Regulatory alignment increases probability of timely trial initiation and eventual data that could enable licensing, partnerships, or larger funding rounds.
Bears Say
Pre-revenue With Rising Cash BurnSustained negative operating and free cash flow (~-$10.7M TTM) without commercial revenue creates persistent funding dependence. Over the medium term this raises dilution and liquidity risks, constraining R&D pacing and partner negotiation leverage unless substantial external capital is secured.
Historically Weak Balance Sheet And Limited Asset BaseImproved reported equity masks prior negative equity and a small asset base (~$11.6M). High debt-to-equity signals mixed leverage metrics. This limited financial cushion reduces resilience to trial delays or cost overruns and increases reliance on timely external financing.
Single‑asset, High Clinical Execution RiskAs a development-stage firm concentrated on SIL204, company value is highly contingent on clinical success and regulatory approvals. A single pivotal program creates binary outcomes: trial failure or delay would materially impair prospects, while success is required to sustain long‑term commercial viability.
Silexion Therapeutics News
SLXN FAQ
What was Silexion Therapeutics’s price range in the past 12 months?
Silexion Therapeutics lowest stock price was $1.51 and its highest was $26.70 in the past 12 months.
What is Silexion Therapeutics’s market cap?
Silexion Therapeutics’s market cap is $4.94M.
When is Silexion Therapeutics’s upcoming earnings report date?
Silexion Therapeutics’s upcoming earnings report date is Mar 24, 2026 which is in 32 days.
How were Silexion Therapeutics’s earnings last quarter?
Silexion Therapeutics released its earnings results on Nov 12, 2025. The company reported -$2.88 earnings per share for the quarter, beating the consensus estimate of -$3.4 by $0.52.
Is Silexion Therapeutics overvalued?
According to Wall Street analysts Silexion Therapeutics’s price is currently Undervalued.
Does Silexion Therapeutics pay dividends?
Silexion Therapeutics does not currently pay dividends.
What is Silexion Therapeutics’s EPS estimate?
Silexion Therapeutics’s EPS estimate is -1.12.
How many shares outstanding does Silexion Therapeutics have?
Silexion Therapeutics has 3,126,642 shares outstanding.
What happened to Silexion Therapeutics’s price movement after its last earnings report?
Silexion Therapeutics reported an EPS of -$2.88 in its last earnings report, beating expectations of -$3.4. Following the earnings report the stock price went up 3.559%.
Which hedge fund is a major shareholder of Silexion Therapeutics?
Currently, no hedge funds are holding shares in SLXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Silexion Therapeutics
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
SLXN Stock 12 Month Forecast
Average Price Target
$9.00
▲(324.53% Upside)